03.10.2022 - Statistically Significant Reduction in CV Mortality and HF Rehospitalizations as Compared to IV Diuretics at 30 and 90 DaysMINNEAPOLIS, Oct. 03, 2022 (GLOBE NEWSWIRE) - Nuwellis, Inc. (Nasdaq: NUWE), a commercial-stage company focused on . Seite 1
Nuwellis Announces First Patient Enrolled in its Pivotal Trial REVERSE-HF forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.
Nuwellis Announces IRB Approval to Begin Its REVERSE-HF Clinical Study streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.